LEXINGTON, Mass., April 6 /PRNewswire/ -- Ardais Corporation, the leading provider of clinical data and biomaterials resources for molecular medicine- based drug discovery and development, announced today that it has expanded its collaborative agreement with Aventis to assess the potential of certain biological targets in the pharmaceutical company's R&D pipeline. Financial terms were not disclosed.
Under the expanded agreement, Ardais will combine the resources of its Biomaterials and Information for Genomic Research (BIGR(R)) Library of high quality tissues and associated patient data with its immunohistochemistry (IHC) profiling to optimize validation assays and assist in the characterization of each target in panels of normal and diseased human tissues.
"We are very pleased Aventis has chosen to expand its research efforts with Ardais. This expanded agreement is an important milestone that we believe demonstrates the quality of our science," noted Alan Buckler, Chief, CSO, Senior Vice President Research & Development, Ardais Corporation. "This broadened relationship with our colleagues at Aventis also reflects Ardais' value proposition and our growing ability to provide a single point solution to various aspects of molecular medicine."
About Ardais Corporation
Ardais Corporation is the leading provider of clinical data and biomaterials resources for the application of molecular medicine in drug discovery and development. The company is dedicated to improving human subjects-based translational research at academic medical centers, as well as biotechnology and pharmaceutical companies.
Ardais also offers biospecimen management solutions, encompassing deployment and operational management services, biospecimen procurement protocols and software, patient enrollment, clinical data collection and quality management systems. Ardais' unique platform addresses ethical, legal and biological concerns and enables biomedical researchers to collect, annotate, manage and distribute their human biological material resources.
Ardais' expanding biomaterials portfolio, sourced from more than 14,000 patients, has more than 180,000 high quality tissue samples, including: 1. Formalin-fixed and frozen samples with associated clinical information 2. Tissue microarrays for high throughput parallel analyses 3. Molecular derivatives, including RNA, DNA and protein lysates 4. Immunohistochemistry services utilizing both formalin-fixed and frozen tissue resources
For more information, please visit: http://www.ardais.com/.
For information contact:
Feinstein Kean Healthcare